Effectiveness of buprenorphine (naloxone) for opioid dependence does not differ across opioid categories: a retrospective cohort study from India

References

• Ahmadi, J. 2002. A controlled trial of buprenorphine treatment for opium dependence: The first experience from Iran. Drug and Alcohol Dependence 66 (2):111–14. doi:10.1016/S0376-8716(01)00202-2.
   PubMed Web of Science ®Google Scholar
• Ahmadi, J., M. Babaee-Beigi, M. Alishahi, I. Maany, and T. Hidari. 2004. Twelve-month maintenance treatment of opium-dependent patients. Journal of Substance Abuse Treatment 26 (1):61–64. doi:10.1016/S0740-5472(03)00141-7.
   Web of Science ®Google Scholar
• Ahmadi, J., and N. Bahrami. 2002. Buprenorphine treatment of opium-dependent outpatients seeking treatment in Iran. Journal of Substance Abuse Treatment 23 (4):415–17. doi:10.1016/s0740-5472(02)00272-6.
   PubMed Web of Science ®Google Scholar
• Ambekar, A., A. Agrawal, R. Rao, A. K. Mishra, S. K. Khandelwal, and R. C. (2019). Ministry of social justice and empowerment magnitude of substance use. https://www.muktangan.org/pdf/Magnitude_Substance_Use_India_REPORT.pdf
   Google Scholar
• Ashrafi, A., D. Dahanayake, A. Ghosh, M. Jang, B. Kafle, S. J. Kantipudi, V. Kapil, R. Masri, R. Lili, S. Sahoo, et al. 2020. Homelessness and mental illness: views from early career psychiatrists from Asian Countries. World Social Psychiatry 2 (3):196. doi:10.4103/WSP.WSP_11_20.
   Google Scholar
• Auriacombe, M., P. Franques, and J. Tignol. 2001. Deaths attributable to methadone vs buprenorphine in France. JAMA 285 (1):45. doi:10.1001/jama.285.1.39.
   PubMed Web of Science ®Google Scholar
• Avasthi, A. 2010. Preserve and strengthen family to promote mental health. Indian Journal of Psychiatry 52 (2):113. doi:10.4103/0019-5545.64582.
   PubMedGoogle Scholar
• Degenhardt, L., F. Charlson, A. Ferrari, D. Santomauro, H. Erskine, A. Mantilla-Herrara, H. Whiteford, J. Leung, M. Naghavi, M. Griswold, et al. 2018. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. The Lancet Psychiatry 5 (12):987. doi:10.1016/S2215-0366(18)30337-7.
   PubMed Web of Science ®Google Scholar
• Degenhardt, L., J. Grebely, J. Stone, M. Hickman, P. Vickerman, B. D. L. Marshall, J. Bruneau, F. L. Altice, G. Henderson, A. Rahimi-Movaghar, et al. 2019. Global patterns of opioid use and dependence: Harms to populations, interventions, and future action. Lancet (London, England) 394 (10208):1560–79. doi:10.1016/S0140-6736(19)32229-9.
   PubMed Web of Science ®Google Scholar
• Drinking Highest Among Educated, Upper-Income Americans. (n.d.) Retrieved January 6, 2023, from https://news.gallup.com/poll/184358/drinking-highest-among-educated-upper-income-americans.aspx
   Google Scholar
• Fareed, A., S. Vayalapalli, J. Casarella, and K. Drexler. 2012. Effect of buprenorphine dose on treatment outcome. Journal of Addictive Diseases 31 (1):8–18. doi:10.1080/10550887.2011.642758.
   PubMed Web of Science ®Google Scholar
• Golan, O. K., R. Totaram, E. Perry, K. Fortson, R. Rivera-Atilano, R. Entress, M. Golan, B. Andraka-Christou, D. Whitaker, and T. Pigott. 2022. Systematic review and meta-analysis of changes in quality of life following initiation of buprenorphine for opioid use disorder. Drug and Alcohol Dependence 235:109445. doi:10.1016/J.DRUGALCDEP.2022.109445.
   PubMed Web of Science ®Google Scholar
• Goodman, E., and B. Huang. 2002. Socioeconomic status, depressive symptoms, and adolescent substance use. Archives of Pediatrics & Adolescent Medicine 156 (5):448–53. doi:10.1001/ARCHPEDI.156.5.448.
   PubMed Web of Science ®Google Scholar
• Greenwald, M., C. E. Johanson, D. Moody, J. H. Woods, M. R. Kilbourn, R. A. Koeppe, C. R. Schuster, and J.-K. Zubieta. 2003. Effects of buprenorphine maintenance dose on μ-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacol 28:2000–09. doi:10.1038/sj.npp.1300251.
   PubMed Web of Science ®Google Scholar
• Hanson, M. D., and E. Chen. 2007. Socioeconomic status and health behaviors in adolescence: A review of the literature. Journal of Behavioral Medicine 30 (3):263–85. doi:10.1007/S10865-007-9098-3.
   PubMed Web of Science ®Google Scholar
• Havens, J. R., C. A. Latkin, M. Pu, L. J. Cornelius, D. Bishai, S. Huettner, C. Rapp, E. P. Ricketts, J. J. Lloyd, and S. A. Strathdee. 2009. Predictors of opiate agonist treatment retention among injection drug users referred from a needle exchange program. Journal of Substance Abuse Treatment 36 (3):306–12. doi:10.1016/J.JSAT.2008.07.002.
   PubMed Web of Science ®Google Scholar
• Huckle, T., R. Q. You, and S. Casswell. 2010. Socio-economic status predicts drinking patterns but not alcohol-related consequences independently. Addiction (Abingdon, England) 105 (7):1192–202. doi:10.1111/J.1360-0443.2010.02931.X.
   PubMed Web of Science ®Google Scholar
• Huerta, M. C., and F. Borgonovi. 2010. Education, alcohol use and abuse among young adults in Britain. Social Science & Medicine 71 (1):143–51. doi:10.1016/J.SOCSCIMED.2010.03.022.
   PubMed Web of Science ®Google Scholar
• Klimas, J., M. A. Hamilton, L. Gorfinkel, A. Adam, W. Cullen, and E. Wood. 2021. Retention in opioid agonist treatment: A rapid review and meta-analysis comparing observational studies and randomized controlled trials. Systematic Reviews 10 (1):216. doi:10.1186/s13643-021-01764-9.
   PubMed Web of Science ®Google Scholar
• Korownyk, C., D. Perry, J. Ton, M. R. Kolber, S. Garrison, B. Thomas, G. M. Allan, N. Dugré, C. R. Finley, R. Ting, et al. 2019. Opioid use disorder in primary care. Canadian Family Physician 65 (5):E194–E206.
   PubMed Web of Science ®Google Scholar
• Kumar, G., P. Dash, J. Patnaik, and G. Pany. 2022. SOCIOECONOMIC STATUS SCALE-MODIFIED KUPPUSWAMY SCALE for the YEAR 2022. International Journal of Community Dentistry 10 (1):1–6. doi:10.56501/INTJCOMMUNITYDENT.V10I1.26.
   Google Scholar
• Luthar, S. S., and A. S. Goldstein. 2008. Substance use and related behaviors among suburban late adolescents: The importance of perceived parent containment. Development and Psychopathology 20 (2):591. doi:10.1017/S0954579408000291.
   PubMed Web of Science ®Google Scholar
• Mattick, R. P., C. Breen, J. Kimber, and M. Davoli. 2014. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews 2014 (2). doi: 10.1002/14651858.CD002207.pub4.
   PubMedGoogle Scholar
• McClure, E. A., A. N. C. Campbell, M. Pavlicova, M. Hu, T. Winhusen, R. G. Vandrey, L. M. Ruglass, L. S. Covey, M. L. Stitzer, T. L. Kyle, et al. 2015. Cigarette smoking during substance use disorder treatment: Secondary outcomes from a national drug abuse treatment clinical trials network study. Journal of Substance Abuse Treatment 53:39. doi:10.1016/J.JSAT.2014.12.007.
   PubMed Web of Science ®Google Scholar
• McDonald R, D., and K. Patel. 2015. The relative risk of fatal poisoning by methadone or buprenorphine within the wider population of England and Wales. British Medical Journal Open 5 (5):e007629. doi:10.1136/BMJOPEN-2015-007629.
   PubMed Web of Science ®Google Scholar
• Mukau, L., K. Wormley, C. Tomaszewski, B. Ahmad, R. Vohra, and A. A. Herring. 2022. Buprenorphine for high-dose tramadol dependence: A case report of successful outpatient treatment. Clinical Practice and Cases in Emergency Medicine 6 (1):83. doi:10.5811/CPCEM.2021.12.54602.
   PubMedGoogle Scholar
• Nielsen, S., W. C. Tse, and B. Larance. 2022. Opioid agonist treatment for people who are dependent on pharmaceutical opioids. Cochrane Database of Systematic Reviews 2022 (9). doi: 10.1002/14651858.CD011117.pub3.
   Google Scholar
• Rahimi-Movaghar, A., M. Amin-Esmaeili, M. Hefazi, and R. Yousefi-Nooraie. 2013. Pharmacological therapies for maintenance treatments of opium dependence. Cochrane Database of Systematic Reviews 2013 (1). doi: 10.1002/14651858.CD007775.pub2.
   Google Scholar
• Ritvo, J. I., R. Koonce, C. C. Thurstone, and H. L. Causey. 2007. Tramadol dependence: Treatment with buprenorphine/naloxone. The American Journal on Addictions 16 (1):67–68. doi:10.1080/10550490601080118.
   PubMed Web of Science ®Google Scholar
• Sadek, J., and J. Saunders. 2022. Treatment retention in opioid agonist therapy: Comparison of methadone versus buprenorphine/naloxone by analysis of daily-witnessed dispensed medication in a Canadian Province. BMC Psychiatry 22 (1). doi: 10.1186/S12888-022-04175-9.
   PubMed Web of Science ®Google Scholar
• Santo, T., Jr, B. Clark, M. Hickman, J. Grebely, G. Campbell, L. Sordo, A. Chen, L. T. Tran, C. Bharat, P. Padmanathan, et al. 2021. Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: A systematic review and meta-analysis. JAMA Psychiatry 78 (9):979–93. doi:10.1001/jamapsychiatry.2021.0976.
   PubMed Web of Science ®Google Scholar
• Sarkar, S., N. Nebhinani, S. M. Singh, S. K. Mattoo, and D. Basu. 2012. Tramadol dependence: A case series from India. Indian Journal of Psychological Medicine 34 (3):283–85. doi:10.4103/0253-7176.106038.
   PubMedGoogle Scholar
• Sordo, L., G. Barrio, M. J. Bravo, B. I. Indave, L. Degenhardt, L. Wiessing, M. Ferri, and R. Pastor-Barriuso. 2017. Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies. BMJ (Clinical Research Ed) 357:j1550. doi:10.1136/BMJ.J1550.
   PubMed Web of Science ®Google Scholar
• Tjäderborn, M., A. K. Jönsson, J. Ahlner, and S. Hägg. 2009. Tramadol dependence: A survey of spontaneously reported cases in Sweden. Pharmacoepidemiology and Drug Safety 18 (12):1192–98. doi:10.1002/PDS.1838.
   PubMed Web of Science ®Google Scholar
• United Nations Office on Drugs and Crime. (2022). World drug report 2022 Annex. https://www.unodc.org/unodc/en/data-and-analysis/world-drug-report-2022.html
   Google Scholar
• van Draanen, J., C. Tsang, S. Mitra, M. Karamouzian, and L. Richardson. 2020. Socioeconomic marginalization and opioid-related overdose: A systematic review. Drug and Alcohol Dependence 214:108127. doi:10.1016/J.DRUGALCDEP.2020.108127.
   PubMedGoogle Scholar